Search
AAV1-FS344
go.drugbank.com/drugs/DB17855InvestigationalAAV1-FS344 is an investigational gene therapy developed by Milo Biotechnology to deliver follistatin, a potent myostatin inhibitor.
Tezosentan
go.drugbank.com/drugs/DB06558InvestigationalTezosentan is an intravenous endothelin receptor A/B antagonist.
Plitidepsin
go.drugbank.com/drugs/DB04977InvestigationalAplidine is also of interest as a potential treatment for some leukemias. … Aplidine is a peptide found in tunicates which shows promise in shrinking tumors in pancreatic, stomach, bladder, and prostate cancers. The specific marine organism is _Aplidium albicans_.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesHuman ciliary neurotrophic factor, recombinant (E. coli)
go.drugbank.com/drugs/DB17959ExperimentalThe trials were NCT03071965, an extension study of the NT-501 CNTF implant for macular telangiectasia, and NCT01949324, a Phase 2 multicenter randomized clinical trial of CNTF for macular telangiectasia
VY-HTT01
go.drugbank.com/drugs/DB16999InvestigationalVY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA. … VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression.
Celivarone
go.drugbank.com/drugs/DB16012InvestigationalCelivarone is under investigation in clinical trial NCT00233441 (Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 Mg OD With Amiodarone as
Contusugene ladenovec
go.drugbank.com/drugs/DB05322InvestigationalAdvexin is a well-tolerated and efficacious treatment for numerous cancers, both as monotherapy and in combination with radiation and/or chemotherapy agents. … INGN 201(Advexin) is a replication-impaired adenoviral vector that carries the p53 gene, has been evaluated in both preclinical and clinical trials.
VX-702
go.drugbank.com/drugs/DB05470InvestigationalVX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA). It acts as a p38 MAP kinase inhibitor. … In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA.
UDP-alpha-D-glucuronic acid
go.drugbank.com/drugs/DB03041ExperimentalA nucleoside diphosphate sugar which serves as a source of glucuronic acid for polysaccharide biosynthesis.
(S)-Warfarin
go.drugbank.com/drugs/DB14055InvestigationalS-warfarin is 2-5 times more potent than the R-isomer in producing an anticoagulant response.[A7166] … Warfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C18 Substrates